Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple vaccine policy change save thousands of Children's lives?

NCT ID NCT01306006

Completed ⭐️ VACCINE ⭐️ Sponsor: Bandim Health Project Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study in Guinea-Bissau tests a new policy: giving the measles vaccine to all children up to 35 months old, instead of only those under 12 months. Researchers think the vaccine may have extra health benefits beyond preventing measles, possibly cutting deaths by half. Around 3,500 children will be randomly assigned to either the current age-limited policy or the broader policy, and researchers will track who survives.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
measles vaccine
What this could lead to
If successful, this could show that giving measles vaccine to older children saves more lives than the current age-limited policy, potentially changing vaccination guidelines worldwide.
What could go wrong
This is a single-country study with 3500 children, and results may not apply elsewhere. The vaccine's non-specific effects are still not fully understood, and the trial cannot guarantee a 50% mortality reduction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MORTALITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MORTALITY VACCINES

Contacts and locations

Locations

  • Bandim Health Project

    Bissau, Guinea-Bissau

More trials for these conditions

Other studies related to the condition(s) this trial covers.